Up to half of patients with VHL develop malignant renal lesions. Urologists handling these cases are faced with the challenge of optimizing control of often bilateral multifocal tumors while maximizing preservation of kidney function. Robert Grubb and colleagues assess the relative merits of different management strategies, and present the molecular processes underlying VHL that might be targeted by new treatments.
- Robert L Grubb III
- Peter L Choyke
- McClellan M Walther
